Evidence map›Paper›PMID 41708931›Full record

ArticleAnnals of surgical oncology2026

Second Ipsilateral Breast Cancer Event: True Recurrence, New Primary, or True Recurrence Like? : Breast Cancer Local Recurrence.

Nina Pujol, Jocelyn Gal, Mathieu Gautier, Yassine Rizzi, Flora Courtault-Deslandes, Renaud Schiappa, Jean-Michel Hannoun-Levi

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nina PujolDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, Cedex, France.
Jocelyn GalDepartment of Biostatistics, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, France.
Mathieu GautierDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, Cedex, France.
Yassine RizziDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, Cedex, France.
Flora Courtault-DeslandesDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, Cedex, France.
Renaud SchiappaDepartment of Biostatistics, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, France.
Jean-Michel Hannoun-LeviDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, Cedex, France. jean-michel.hannoun-levi@nice.unicancer.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the case of a second ipsilateral breast cancer event (2

methodsPatients experiencing a second iBCE with a second BCT (lumpectomy + brachytherapy) were retrospectively analyzed. Histology (type, grade, hormone receptor [HR], human epidermal growth factor receptor 2 [HER2] status) and second iBCE topography were used to determine TR and NP. Oncologic outcomes of TR and NP were compared by cumulative incidence rate of second local relapse (CI-2

resultsFrom September 2000 to January 2024, 113 patients met the inclusion criteria (76 TR patients, 37 NP patients). The median age was 52.1 years for the first and 65.4 years for the second iBCE. The median interval between the two breast surgeries (TI

conclusionThis study suggests that TR and NP dichotomy based on tumor histology and topography does not necessarily support TR therapeutic consequences. In case of late TR, a second BCT could be carefully discussed for patients who wish to preserve their breast.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasms, Second PrimaryAdultAgedBrachytherapyFemaleFollow-Up StudiesHumansMiddle AgedPrognosisRetrospective StudiesSurvival RateIpsilateral breast cancer recurrenceMastectomyNew primarySecond breast conserving therapySystemic therapyTrue recurrence

Identifiers

PMID41708931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.